Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer

PAM50/Prosigna gene expression-based assay identifies three categorical risk of relapse groups (ROR-low, ROR-intermediate and ROR-high) in post-menopausal patients with estrogen receptor estrogen receptor-positive (ER+)/ HER2-negative (HER2-) early breast cancer. Low risk patients might not need adj...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Oncotarget
Главные авторы: Fernand ez-Martinez, Aranzazu, Pascual, Tomás, Perrone, Giuseppe, Morales, Serafin, de la Haba, Juan, González-Rivera, Milagros, Galván, Patricia, Zalfa, Francesca, Amato, Michela, Gonzalez, Lucia, Prats, Miquel, Rojo, Federico, Manso, Luis, Paré, Laia, Alonso, Immaculada, Albanell, Joan, Vivancos, Ana, González, Antonio, Matito, Judit, González, Sonia, Fernandez, Pedro, Adamo, Barbara, Muñoz, Montserrat, Viladot, Margarita, Font, Carme, Aya, Francisco, Vidal, Maria, Caballero, Rosalía, Carrasco, Eva, Altomare, Vittorio, Tonini, Giuseppe, Prat, Aleix, Martin, Miguel
Формат: Artigo
Язык:Inglês
Опубликовано: Impact Journals LLC 2017
Предметы:
Research Paper
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5400635/
https://ncbi.nlm.nih.gov/pubmed/28423537
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.15748
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы